Abstract:Resistance to radiation therapy significantly affects the prognosis of solid tumors. Histone deacetylase 6 (HDAC6) is a stress-responsive lysine deacetylase that has emerged as a promising target for cancer therapy, with numerous clinical trials investigating interventions to modulate its activity. While HDAC6 appears to be linked to responses to DNA-damaging therapeutics, the reported responses and underlying mechanisms remain intriguing and varied. In this study, we elucidate a novel mechanism of radioresistance mediated by HDAC6 in non-small cell lung cancer (NSCLC). We classified nine NSCLC cell lines into three groups based on their radioresistance using survival assays and correlated this resistance with the induced expression of six deacetylases. We conducted gain-of-function experiments (GOF) using plasmid transfection and loss-of-function experiments (LOF) employing inhibitors or RNAi. Furthermore, we quantified the repair of damaged dsDNA through FACS-based GFP assays and assessed the mechanism of homologous recombination repair (HRR) end-resection via single-strand quantitative PCR. Co-immunoprecipitation assays, cancer stem cell enrichment, DNA damage-induced senescence assays, reverse-phase protein assays (RPPA), and RNA sequencing were also performed to investigate gene expression changes resulting from the loss of HDAC6. Our findings revealed that HDAC6 induction by radiation is strongly correlated with NSCLC resistance to radiation leading to CSC survival and escape from radiation led senescence LOF of HDAC6 through RNAi or inhibitors suppressed resistance, while GOF achieved through wild-type or deacetylase activity-deficient mutant transfection, induced resistance. Importantly, this resistance mechanism was independent of deacetylation activity. RNAi-mediated loss of HDAC6 reduced both HRR and non-homologous end-joining, whereas pharmacological inhibition of HDAC6 activity did not. Notably, DNA end-resection, a critical step in HRR, was decreased by RNA interference but not affected by the inhibitors. RPPA assays demonstrated that Histone demethylase 1A (LSD1/KDM1A) levels decreased significantly upon HDAC6 RNA interference but remained unaffected by pharmacological intervention. Loss of LSD1 alone resulted in decreased HRR and end-resection, likely mediated through HDAC6-induced ubiquitination. Moreover, overexpression of LSD1 rescued the HDAC6 loss-induced sensitization of NSCLCs. In summary, our study unveils a novel mechanism by which HDAC6 mediates HRR after radiation through the stabilization of LSD1. This mechanism operates independently of deacetylase activity. Therefore, our findings suggest that interventions targeting both deacetylation and non-deacetylation roles of HDAC6 should be considered to overcome HDAC6-derived radioresistance in NSCLCs and enhances the radiation therapy efficacy. Citation Format: Sojung Ha, Hyejin Kim, Hani Lee, Seokgyeong Choi, Ho-young Lee, Woo-Young Kim. HDAC6 mediates the radioresistance of NSCLC through LSD1, independent of its own deacetylation activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2883.

JMJD6 promotes radioresistance of non-small cell lung cancer via epigenetic regulation of EHF

JMJD5 Inhibits Lung Cancer Progression by Facilitating EGFR Proteasomal Degradation

632PPatient-derived xenografts (PDX) identify JMJD6 inhibitor as an effective therapeutic medicine in colorectal cancer

The role of JMJD2A in immune evasion and malignant behavior of esophageal squamous cell carcinoma

JMJD1A Promotes Tumorigenesis and Forms a Feedback Loop with EZH2/let-7c in NSCLC Cells

c‐Jun‐mediated JMJD6 restoration enhances resistance of liver cancer to radiotherapy through the IL‐4‐activated ERK pathway

Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response

JMJD6–BRD4 Complex Stimulates Lncrna HOTAIR Transcription by Binding to the Promoter Region of HOTAIR and Induces Radioresistance in Liver Cancer Stem Cells

JMJD3 Facilitates C/EBPβ-centered Transcriptional Program to Exert Oncorepressor Activity in AML

High Expression of JMJD6 Predicts Unfavorable Survival in Lung Adenocarcinoma

JMJD3 Enhances Invasiveness and Migratory Capacity of Non-Small Cell Lung Cancer Cell Via Activating EMT Signaling Pathway.

Targeting HMGB3/hTERT axis for radioresistance in cervical cancer.

Epigenome Screening Highlights That JMJD6 Confers an Epigenetic Vulnerability and Mediates Sunitinib Sensitivity in Renal Cell Carcinoma.

Targeting HMGB3/hTERT Axis for Radioresistance in Cervical Cancer

JMJD3 Promotes Esophageal Squamous Cell Carcinoma Pathogenesis Through Epigenetic Regulation of MYC

Abstract 2883: HDAC6 mediates the radioresistance of NSCLC through LSD1, independent of its own deacetylation activity

Jumonji Domain-Containing Protein 6 Functions As a Marker of Head and Neck Squamous Cell Carcinoma at Advanced Stage with No Effect on Prognosis

Effects of MLL5 and HOXA regulated by NRP1 on radioresistance in A549

JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

M6a Regulators Featured by Tumor Immune Microenvironment Landscapes and Correlated with Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer